CORRECTION Open Access



Correction: Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis

Zhe Dong^{1†}, Gao-Yuan Wang^{1†}, Dong-Yu Dai¹, Guan-Jie Qin¹, Ling-Long Tang¹, Cheng Xu^{1*} and Jun Ma^{1*}

Correction to: BMC Cancer 24, 466 (2024) https://doi.org/10.1186/s12885-024-12189-7

Following publication of the original article [1], the author reported a typesetting error, whereby Tables 1, 2 and 3 were erroneously omitted from the published version. The publishers apologise for this error. The omitted Tables 1, 2 and 3 are given below. The original article [1] has been corrected.

[†]Zhe Dong and Gao-Yuan Wang contributed equally to this work.

The online version of the original article can be found at https://doi.org/10.1186/s12885-024-12189-7.

*Correspondence: Cheng Xu xucheng@sysucc.org.cn Jun Ma maiun2@mail.sysu.edu.cn

¹Départment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Dong et al. BMC Cancer (2024) 24:528 Page 2 of 5

 Table 1
 Patient characteristics

Characteristics	With PET/CT	Without PET/C1
	N=132 (%)	N=319 (%)
Age (years)		
< 45	65 (49.2%)	169 (53.0%)
≥ 45	67 (50.8%)	150 (47.0%)
Sex		
Male	106 (80.3%)	238 (74.6%)
Female	26 (19.7%)	81 (25.4%)
rEBV DNA (copies/ml)		
Undetectable	48 (36.4%)	105 (32.9%)
Detectable	69 (52.3%)	167 (52.4%)
Unkown	15 (11.4%)	47 (14.7%)
rLactate dehydrogenase (U/L)	,	, ,
< 240	117 (88.6%)	247 (77.4%)
≥ 240	5 (3.8%)	7 (2.2%)
Unkown	10 (7.6%)	65 (20.4%)
rC-reactive protein (mg/L)	. (,	,
< 10.5	107 (81.1%)	218 (68.3%)
≥ 10.5	18 (13.6%)	30 (9.4%)
Unkown	7 (5.3%)	71 (22.3%)
rAlbumin (g/L)	(0.07.7)	(,
<39.4	4 (3.0%)	30 (9.4%)
≥ 39.4	121 (91.7%)	224 (70.2%)
Unkown	7 (5.3%)	65 (20.4%)
rNLR	(0.07.7)	(,
< 3.7	89 (67.4%)	189 (59.2%)
≥ 3.7	41 (31.1%)	108 (33.9%)
Unkown	2 (1.5%)	22 (6.9%)
rT category*	2 (1.570)	22 (8.5 76)
rT0-rT2	91 (68.9%)	228 (71.5%)
rT3-rT4	41 (31.1%)	91 (28.5%)
rN category*	(370)	31 (28.870)
rN0	80 (60.6%)	159 (49.8%)
rN1-rN3	52 (39.4%)	160 (50.2%)
rStage*	32 (37.170)	100 (30.270)
r0-rll	78 (59.1%)	199 (62.4%)
rIII-rIVA	54 (40.9%)	120 (37.6%)
Intial stage	31 (10.570)	120 (37.370)
I-II	23 (17.4%)	51 (16.0%)
III-IVA	109 (82.6%)	268 (84.0%)
Pathological examination sites	103 (02.070)	200 (01.070)
Primary tumor	79 (59.8%)	172 (53.9%)
Regional lymph nodes	50 (37.9%)	172 (33.9%)
Both	3 (2.3%)	9 (2.8%)
Treatment	/۱۵/ د.٤ د	9 (2.070)
Salvage Surgery	60 (45.5%)	160 (50.2%)
Re-radiotherapy	60 (43.5%) 48 (36.4%)	84 (26.3%)
Palliative treatment	48 (30.4%) 24 (18.2%)	75 (23.5%)

 $Abbreviations \ r: Recurrent; EBV: epstein-barr virus; NLR: neutrophil-to-lymphocyte \ ratio; PET/CT: positron \ emission \ tomography/computed \ tomography$

 $^{^*}$ Based on the eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) according to MRI

Dong et al. BMC Cancer (2024) 24:528 Page 3 of 5

Table 2 Univariate and multivariate Cox regression analysis for overall survival in the rlll-IVA* NPC

Characteristics	Univariable analysis	P	Multivariate analysis	P
	HR (95% CI)		HR (95% CI)	
Age (years)				
< 45	1 (reference)			
≥ 45	1.090 (0.685-1.733)	0.717		
Sex				
Male	1 (reference)			
Female	1.372 (0.775-2.428)	0.278		
rEBV DNA (copies/ml)				
Undetectable	1 (reference)			
Detectable	1.612 (0.899-2.889)	0.109		
Unkown				
rLactate dehydrogenase (U/L)				
< 240	1 (reference)			
≥ 240	1.104 (0.347-3.518)	0.867		
Unkown	/			
rC-reactive protein (mg/L)				
< 10.5	1 (reference)		1 (reference)	
≥ 10.5	2.784 (1.615-4.798)	<0.001	2.348 (1.336-4.127)	0.003
rAlbumin (g/L)				
< 39.4	1 (reference)		1 (reference)	
≥ 39.4	0.195 (0.107-0.356)	<0.001	0.224 (0.120-0.418)	<0.001
rNLR				
< 3.7	1 (reference)			
≥ 3.7	1.372 (0.855-2.203)	0.190		
Unkown	/			
Treatment				
Palliative treatment	1 (reference)		1 (reference)	
Re-radiotherapy+Salvage Surgery	0.340 (0.210-0.551)	<0.001	0.407 (0.249-0.666)	<0.001
PET/CT				
No	1 (reference)		1 (reference)	
Yes	0.519 (0.294-0.917)	0.024	0.476 (0.267-0.847)	0.012

Abbreviations r: Recurrent; EBV: epstein-barr virus; NLR: neutrophil-to-lymphocyte ratio; HR: hazard ratio; 95% CI: 95% confidence interval; NPC: nasopharyngeal carcinoma; MRI: magnetic resonance imaging; PET/CT: positron emission tomography/computed tomography

^{*}Based on the eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system according to MRI Using the Cox regression model to calculate HR and 95% CI

Dong et al. BMC Cancer (2024) 24:528 Page 4 of 5

Characteristics	Univariable analysis HR (95% CI)	Р	Multivariate analysis HR (95% CI)	P
Age (years)		0.034		0.040
< 45	1 (reference)		1 (reference)	
≥ 45	2.277 (1.064-4.873)		2.293 (1.037-5.074)	
Sex		0.964		
Male	1 (reference)			
Female	0.978 (0.373-2.562)			
rEBV DNA (copies/ml)		0.691		
Undetectable	1 (reference)			
Detectable	1.165 (0.548-2.475)			
rLactate dehydrogenase (U/L)		0.620		
< 240	1 (reference)			
≥ 240	0.603 (0.082-4.446)			
rC-reactive protein (mg/L)		< 0.001		0.003
< 10.5	1 (reference)		1 (reference)	
≥ 10.5	4.465 (2.064-9.660)		3.552 (1.560-8.087)	
rNLR	, , , , , , , , , , , , , , , , , , , ,	0.344	,	
< 3.7	1 (reference)			
≥ 3.7	1.445 (0.675-3.095)			
rT category#	, , , , , , , , , , , , , , , , , , , ,	0.062		
rT0-2	1 (reference)			
rT3-4	2.122 (0.962-4.683)			
rN category [#]	(,	0.372		
rNO	1 (reference)	****		
rN1-3	0.716 (0.344-1.49)			
rStage [#]	<i>a.</i> 10 (6.5 1 1 1.15)	0.133		
r0-rII	1 (reference)	0.133		
rIII-rIVA	1.745 (0.843-3.608)			
rT category*	15 (6.6.15 5.666)	0.010		
rT0-2	1 (reference)	0.010		
rT3-4	2.684 (1.263-5.703)			
rN category*	2.56 1 (1.265 5.765)	0.701		
rNO	1 (reference)	0.701		
rN1-3	0.868 (0.423-1.784)			
rStage*	0.000 (0.425 1.704)	0.023		0.036
r0-rll	1 (reference)	0.023	1 (reference)	0.030
rIII-rIVA	2.600 (1.143-5.916)		2.662 (1.066-6.649)	
Treatment	2.000 (1.173-3.210)	0.019	2.002 (1.000-0.043)	0.316
Palliative treatment	1 (reference)	0.019	1 (reference)	0.510
Re-radiotherapy+Salvage Surgery	0.379 (0.168-0.853)		0.653 (0.284-1.502)	
PET/CT SUVmax	U.3/3 (U.1U0-U.033)	0.015	0.033 (0.204-1.302)	0.179
< 11.9	1 (reference)	0.015	1 (reference)	0.179
< 11.9 ≥11.9	2.464 (1.195-5.078)		1.730 (0.777-3.852)	

Abbreviations r: Recurrent; EBV: epstein-barr virus; NLR: neutrophil-to-lymphocyte ratio; HR: hazard ratio; 95% CI: 95% confidence interval; NPC: nasopharyngeal $carcinoma; MRI: magnetic \ resonance \ imaging; PET/CT: positron \ emission \ tomography/computed \ tomography; SUV max: maximum \ standardized \ uptake \ value$ #Based on the eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system according to MRI *Based on the eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system according to PET/CT Using the Cox regression model to calculate HR and 95% CI

Dong et al. BMC Cancer (2024) 24:528 Page 5 of 5

Published online: 25 April 2024

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

 Dong Z, Wang GY, Dai DY, et al. Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis. BMC Cancer. 2024;24:466. https://doi.org/10.1186/s12885-024-12189-7.